Lantheus Medical Imaging Finalized Merger with Progenics Pharmaceuticals
Council member Lantheus Medical Imaging (LMI) has completed its merger with Progenics Pharmaceuticals, an innovative oncology company.
The merger, first announced in 2019, will combine LMI’s extensive manufacturing experience and Progenics’s cancer drugs and developmental capabilities. Through the merger, LMI will obtain not only research resources, but three leading cancer products approved by the Food and Drug Administration (FDA). LMI seeks to utilize the artificial intelligence and targeted medicine technology developed by the oncology company to expand its imagining services.
“Today marks an important day for Lantheus and Progenics. This combination forms an innovative company with a diversified diagnostics and therapeutics portfolio,” said Mary Anne Heino, Lantheus President and Chief Executive Officer. “We’re excited to welcome the talented Progenics employees to the Lantheus organization to help build upon our solid foundation.”
NEC congratulates LMI on this successful merger and looks forward to the expanded company’s continued growth and success. Read more.
Recently from the Blog
NEC Announces COVID In-Person Event Policy; Plans Return to In-Person Programming in 2022
